| Health / Medical Topics |
XL820
An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial growth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression. (NCI Thesaurus)
YOU MAY ALSO LIKE
A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called topoisomerase inhibitors. …
Human XIST wild-type allele is located in the vicinity of Xq13.2 and is approximately 32 kb in length. Rather than encoding a…
This gene may play a role in dosage compensation of the X chromosome.
The cartilage just below the sternal body.
A sulfonamide-based diuretic. Xipamide acts on the distal convoluted tubules. In addition, this agent has a weak inhibitory effect on carbonic anyydrase…
XIAP-associated factor 1 (301 aa, ~35 kDa) is encoded by the human XAF1 gene. This protein plays a role in the regulation…
